Clinical Trials Directory

Trials / Completed

CompletedNCT02089308

Nicotine Patch - Bioequivalence Study

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
74 (actual)
Sponsor
Pierre Fabre Medicament · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine patch to that of a reference formulation following repeated applications

Conditions

Interventions

TypeNameDescription
DRUGTest treatment : V0116 transdermal patch
DRUGReference treatment : Nicotine transdermal patch

Timeline

Start date
2014-03-01
Primary completion
2014-05-01
Completion
2014-05-01
First posted
2014-03-17
Last updated
2014-06-12

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02089308. Inclusion in this directory is not an endorsement.

Nicotine Patch - Bioequivalence Study (NCT02089308) · Clinical Trials Directory